| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005356273 |
| P356 | DOI | 10.1007/S13277-015-3426-Y |
| P698 | PubMed publication ID | 25967454 |
| P2093 | author name string | Haitao Huang | |
| Xueguang Zhang | |||
| Guangbin Li | |||
| Haitao Ma | |||
| Guangbo Zhang | |||
| P2860 | cites work | Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck | Q44592784 |
| Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations | Q46329440 | ||
| Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion | Q46440292 | ||
| Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection | Q46477422 | ||
| CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress | Q46925832 | ||
| Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine | Q60311223 | ||
| Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells | Q64008476 | ||
| Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors | Q70019545 | ||
| Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice | Q71010898 | ||
| Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer | Q73311980 | ||
| Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response | Q80582229 | ||
| CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis | Q81386279 | ||
| Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway | Q81731578 | ||
| Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients | Q82808451 | ||
| Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign | Q84256128 | ||
| Global cancer statistics | Q22241238 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Myeloid-derived suppressor cells: linking inflammation and cancer | Q24641811 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice | Q28377964 | ||
| Myeloid suppressor cell depletion augments antitumor activity in lung cancer | Q28729158 | ||
| Subsets of myeloid-derived suppressor cells in tumor-bearing mice | Q29614297 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells | Q33335471 | ||
| Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells | Q33919954 | ||
| Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics | Q33996767 | ||
| Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells | Q34723007 | ||
| Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy | Q36108095 | ||
| Role of immature myeloid cells in mechanisms of immune evasion in cancer | Q36208862 | ||
| Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma | Q36718963 | ||
| Altered macrophage differentiation and immune dysfunction in tumor development | Q36809767 | ||
| Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity | Q36996588 | ||
| Immune responses to malignancies | Q37040501 | ||
| Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives | Q37118164 | ||
| Deficiency of Kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cells | Q37228480 | ||
| Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. | Q37449181 | ||
| ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment | Q37680218 | ||
| Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact | Q37819005 | ||
| Camouflage and sabotage: tumor escape from the immune system | Q37882478 | ||
| Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. | Q39321728 | ||
| 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity | Q39715226 | ||
| Natural Suppressor (NS) Cells, Neonatal Tolerance, and Total Lymphoid Irradiation: Exploring Obscure Relationships | Q40097097 | ||
| Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer | Q42183073 | ||
| The terminology issue for myeloid-derived suppressor cells | Q42425163 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 7987-7996 | |
| P577 | publication date | 2015-05-14 | |
| P1433 | published in | Tumor Biology | Q15757842 |
| P1476 | title | Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. | |
| P478 | volume | 36 |
| Q38847251 | A clinical and biological perspective of human myeloid-derived suppressor cells in cancer |
| Q95856264 | Comprehensive Analysis of Tumor-Infiltrating Immune Cells and Relevant Therapeutic Strategy in Esophageal Cancer |
| Q38763851 | Emerging immunotherapy for the treatment of esophageal cancer |
| Q38811369 | Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin |
| Q33849679 | HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients. |
| Q38864758 | Myeloid-derived suppressor cells as effectors of immune suppression in cancer. |
| Q57138311 | Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies |
| Q38820842 | Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome |
| Q91565659 | Targeting Tumor Microenvironment by Small-Molecule Inhibitors |
| Q38649547 | The immunobiology of myeloid-derived suppressor cells in cancer |
| Q92422519 | The transcriptional profile of circulating myeloid derived suppressor cells correlates with tumor development and progression in mouse |
| Q46248185 | Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome |
Search more.